Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 18, 2016

Primary Completion Date

July 24, 2017

Study Completion Date

July 24, 2017

Conditions
Sjögren's Syndrome
Interventions
DRUG

BMS-931699

Specified dose on specified days

DRUG

BMS-986142

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (34)

1

Local Institution, Lima Cercado

2050

Local Institution, Camperdown

7600

Local Institution, Stellenbosch

11501

Local Institution, Mineola

11850

Local Institution, Mexico City

15090

Local Institution, Wexford

19104

Local Institution, Philadelphia

28401

Pmg Research Of Wilmington Llc, Wilmington

29118

Acme Research, Llc, Orangeburg

30096

North Georgia Rheumatology Group, Lawrenceville

34239

Local Institution, Sarasota

38305

West Tennessee Research Institute, Jackson

38801

Local Institution, Tupelo

44130

Paramount Medical Research & Consulting, Llc, Middleburg Heights

44650

Local Institution, Guadalajara

56126

Azienda Ospedaliera Universitaria Pisana, Pisa

78745

Tekton Research Inc, Austin

87109

New Mexico Clinical Research & Osteoporosis Center, Albuquerque

91910

Local Institution, Veracruz

92835

St Joseph Heritage Healthcare, Fullerton

94304

Local Institution, Palo Alto

97070

Local Institution, Mérida

121374

Local Institution, Moscow

7501126

Local Institution, Santiago

01605

Clinical Pharmacology Study Group, Worcester

07728

Arthritis And Osteoporosis Associates, Pa, Freehold

16635-8406

Altoona Center For Clinical Research, Duncansville

Unknown

Local Institution, Bogota

Local Institution, Bogotá

Local Institution, Santiago de Cali

LIMA 31

Local Institution, Lima

LIMA 33

Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac, Lima

50-556

Klinika Reumatologii i Chorob Wewnetrznych, Wroclaw

00909

Local Institution, San Juan

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY